{
    "clinical_study": {
        "@rank": "26549", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Other", 
                "description": "Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.\nEach patch will be applied for 24 hours."
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Other", 
                "description": "Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.\nEach patch will be applied for 24 hours."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the relative bioavailability of nicotine following\n      repeated applications of a new transdermal formulation to that of a reference formulation.\n\n      Up to day 7"
        }, 
        "brief_title": "Nicotine Patch - Multidose Bioequivalence Study", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Smokers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subject aged 18 to 45 years (inclusive)\n\n          -  Current Smoker of >or = 5 and < or = 15 cigarettes/day\n\n          -  Fagerstr\u00f6m score < or =5 at selection\n\n          -  Absence of any clinically significant abnormal finding at physical, vital sign,\n             Electrocardiogram ECG, biological examinations in the investigator's opinion.\n\n        Exclusion Criteria:\n\n          -  Presence of any significant medical finding or significant history (in particular any\n             cardio-vascular disease, severe renal or hepatic insufficiency, current gastric or\n             duodenal ulcer) that may impact the safety, the interpretation of the results and/or\n             the participation of the subject in the study according to the opinion of the\n             investigator\n\n          -  Any visible skin disorder, abnormal skin pigmentation or dermatologic disease liable\n             to interfere with use or assessment of transdermal patch"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658215", 
            "org_study_id": "V00116 TD 1 05", 
            "secondary_id": "2011-006213-33"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2"
                ], 
                "intervention_name": "V0116 transdermal patch (Test treatment )", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2"
                ], 
                "intervention_name": "Nicotine transdermal patch (Reference treatment )", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Central Nervous System Agents", 
                "Nicotine polacrilex", 
                "Nicotine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Smoking cessation", 
            "Nicotine", 
            "Tobacco Use Disorder", 
            "Central Nervous System Agents"
        ], 
        "lastchanged_date": "December 10, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rennes", 
                    "country": "France"
                }
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Comit\u00e9 de Protection des Personnes"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinetic profile of nicotine following a repeated patch applications by measuring Maximum Plasma Concentration, Time of Maximum Concentration, Area under the nicotine plasma concentration curve,  for each test and reference formulations", 
            "measure": "Pharmacokinetic profile", 
            "safety_issue": "No", 
            "time_frame": "Blood samples will be collected Day 3 and Day 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658215"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "General and local safety by evaluating the number of subjects with emergent adverse events or changes from baseline to end of study in vital signs, electrocardiogram, haematology and biochemistry", 
            "measure": "Clinical safety (reported adverse events)", 
            "safety_issue": "Yes", 
            "time_frame": "up to day 7"
        }, 
        "source": "Pierre Fabre Medicament", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pierre Fabre Medicament", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}